NASDAQ:ACET Adicet Bio (ACET) Stock Price, News & Analysis $4.89 -0.22 (-4.31%) Closing price 10/14/2026 04:00 PM EasternExtended Trading$4.94 +0.06 (+1.12%) As of 07:58 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About Adicet Bio Stock (NASDAQ:ACET) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Adicet Bio alerts:Sign Up Key Stats Today's Range$4.80▼$5.2750-Day Range$4.89▼$9.7352-Week Range$4.80▼$17.04Volume357,763 shsAverage Volume344,847 shsMarket Capitalization$45.77 millionP/E RatioN/ADividend YieldN/APrice Target$37.80Consensus RatingModerate Buy Company Overview Adicet Bio, Inc. is a clinical-stage biotechnology company focused on developing allogeneic, or “off-the-shelf,” T-cell therapies for cancer and autoimmune diseases. The company’s platform uses gamma delta T cells, a distinct type of immune cell that it engineers with chimeric antigen receptors (CARs) to recognize and attack diseased cells. Adicet’s development programs have included ADI-001, an allogeneic gamma delta CAR T-cell therapy designed to target CD19 on B-cell malignancies, including certain forms of lymphoma. The company has also pursued additional cell therapy candidates intended to address solid tumors and other serious diseases. Its therapies are being evaluated through clinical and preclinical development programs rather than marketed as approved products. Founded in 2014 and headquartered in Redwood City, California, Adicet Bio conducts research and clinical development activities aimed at creating scalable cell therapies that may be administered without using a patient’s own T cells. Chen Schor serves as the company’s president and chief executive officer.AI Generated. May Contain Errors. Read More Adicet Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks70th Percentile Overall ScoreACET MarketRank™: 3.498158863755 of 5 starsAdicet Bio scored higher than 70% of companies evaluated by MarketBeat, and ranked 227th out of 873 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingAdicet Bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 2 strong buy ratings, 5 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialAdicet Bio has a consensus price target of $37.80, representing about 673.0% upside from its current price of $4.89.Amount of Analyst CoverageAdicet Bio has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Adicet Bio's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Adicet Bio are expected to grow in the coming year, from ($6.76) to ($5.64) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Adicet Bio is -0.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Adicet Bio is -0.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAdicet Bio has a P/B Ratio of 0.29. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Adicet Bio's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.37% of the float of Adicet Bio has been sold short.Short Interest Ratio / Days to CoverAdicet Bio has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Adicet Bio has recently increased by 78.49%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAdicet Bio does not currently pay a dividend.Dividend GrowthAdicet Bio does not have a long track record of dividend growth. News and Social Media2.8 / 5News Sentiment0.41 News SentimentAdicet Bio has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Adicet Bio this week, compared to 3 articles on an average week.Search Interest3 people have searched for ACET on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat Follows3 people have added Adicet Bio to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Adicet Bio insiders have not sold or bought any company stock.Percentage Held by Insiders3.40% of the stock of Adicet Bio is held by insiders.Percentage Held by Institutions83.89% of the stock of Adicet Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Adicet Bio's insider trading history. Receive ACET Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adicet Bio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ACET Stock News HeadlinesAnalysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV) and Adicet Bio (ACET)September 30, 2026 | theglobeandmail.comAdicet Bio reports positive Prula-cel phase 1 lupus data as pivotal study plans advanceSeptember 28, 2026 | msn.comReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.October 15 at 1:00 AM | Base Camp Trading (Ad)Adicet Bio, Inc. (ACET) Discusses Positive Prula-cel Data and Plans for Pivotal Study in Lupus Nephritis TranscriptSeptember 28, 2026 | seekingalpha.comAdicet Bio Shares Rise Ahead Of Prula-cel Clinical Data UpdateSeptember 28, 2026 | rttnews.comAdicet Bio Reports Phase 1 Prula-cel Data in Lupus PatientsSeptember 28, 2026 | finance.yahoo.comAdicet Bio Announces Positive Safety and Efficacy Data from Prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus with or without Lupus NephritisSeptember 28, 2026 | businesswire.comAdicet Bio to Host Webcast to Present Prula-cel (formerly ADI-001) Clinical Data in Patients with Systemic Lupus Erythematosus with or without Lupus NephritisSeptember 25, 2026 | businesswire.comSee More Headlines ACET Stock Analysis - Frequently Asked Questions How have ACET shares performed this year? Adicet Bio's stock was trading at $8.42 at the beginning of 2026. Since then, ACET stock has decreased by 41.9% and is now trading at $4.89. How were Adicet Bio's earnings last quarter? Adicet Bio, Inc. (NASDAQ:ACET) announced its quarterly earnings data on Wednesday, August, 5th. The company reported ($1.99) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.69) by $0.30. When did Adicet Bio's stock split? Adicet Bio's stock reverse split on Tuesday, December 30th 2025.The 1-16 reverse split was announced on Friday, December 26th 2025. The number of shares owned by shareholders was adjusted after the market closes on Monday, December 29th 2025. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split. When did Adicet Bio IPO? Adicet Bio (ACET) raised $85 million in an initial public offering (IPO) on Friday, January 26th 2018. The company issued 5,666,667 shares at $14.00-$16.00 per share. How do I buy shares of Adicet Bio? Shares of ACET stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Adicet Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Adicet Bio investors own include NVIDIA (NVDA), Intel (INTC), Micron Technology (MU), Palantir Technologies (PLTR), Rocket Lab (RKLB), Tesla (TSLA) and Ford Motor (F). Company Calendar Last Earnings8/05/2026Today10/15/2026Next Earnings (Estimated)11/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 7 days, ACET's financial health has been in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ACET CIK1720580 Webwww.adicetbio.com Phone(617) 482-2333FaxN/AEmployees102Year Founded2016Price Target and Rating Average Price Target for Adicet Bio$37.80 High Price Target$90.00 Low Price Target$18.00 Potential Upside/Downside+673.0%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($11.45) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$116.80 million Net MarginsN/A Pretax MarginN/A Return on Equity-74.90% Return on Assets-60.87% Debt Debt-to-Equity Ratio0.01 Current Ratio6.71 Quick Ratio6.71 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$16.62 per share Price / Book0.29Miscellaneous Outstanding Shares9,360,000Free Float9,043,000Market Cap$45.77 million OptionableOptionable Beta1.62 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:ACET) was last updated on 10/14/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adicet Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adicet Bio With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
